Medscape www.medscape.com

References for:
Chemotherapy for Pancreatic Cancer

[Aliment Pharmacol Ther 18(11):1049-1069, 2003. © 2003 Blackwell Publishing]

  1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2000; 37: S4-S66.
  2. Fernandez E, La Vecchia C. Porta M et al. Trends in pancreatic cancer mortality in Europe. Int J Cancer 1994; 57: 786-92.
  3. Cancer Statistics in Japan 2001. In: Foundation for the Promotion of Cancer Research. Tokyo: National Cancer Center, 2001: www.ncc.go.jp
  4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics 2001. CA-Cancer J Clin 2001; 51: 15-36.
  5. Carter D, C. Etiology and epidemiology of pancreatic and periampullary cancer. In: Trede, M, Carter, D C, eds. Surgery of the Pancreas, 2nd edn. 2, New York: Churchill Livingstone, 1997: 427-42.
  6. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA-Cancer J Clin 2002; 52: 23-47.
  7. Bramhall S, et al. Epidemiology of pancreatic cancer. In: Beger, HG, Warshaw, A, Carr-Locke, DL, et al., eds. The Pancreas. Boston: Blackwell Scientific, 1998: 889-906.
  8. Haycox A, Lombard M, Neoptolemos J, Walley T. Current treatment and optimal patient management in pancreatic cancer. Aliment Pharmacol Ther 1998; 12: 949-64.
  9. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-5.
  10. Neoptolemos JP, Russell RCG, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients. Br J Surg 1997; 84: 1370-6.
  11. Pasquali C, Sperti C, Filipponi C, Pedrazzoli S. Epidemiology of pancreatic cancer in Northeastern Italy: incidence, resectability rate, hospital stay, costs and survival (1990-1992). Digestive Liver Dis 2002; 34: 723-31.
  12. Sener S, Fremgen A, Menck H, Winchester D. Pancreatic cancer. A report of treatment and survival trends for 100,313 patients diagnosed from 1985 to 1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
  13. Andren-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the new millennium. Pancreatology 2002; 2: 694-6.
  14. Mosca F, Giulianotti PC, Balestracci T, et al. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122: 553-66.
  15. Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995; 75: 2069-76.
  16. Allison D, Piantadosi S, Hruban R, et al. DNA content and other factors associated with ten year survival after resection of pancreatic cancinoma. J Surg Oncol 1998; 67: 151-9.
  17. Nitecki S, Sarr MG, Colby TV, et al. Long term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
  18. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-33; discussion 633-6.
  19. Finlayson E, Birkmeyer J. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg 2003; 196: 410-7.
  20. Neoptolemos J, Cunningham D, Freiss H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003; 14: 675-92.
  21. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703.
  22. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, rand-omised, multicentre trial. Br Med J 1980; 281: 1589-91.
  23. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
  24. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
  25. Oster MW, Gray R, Panasci L, Perry M. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozocin and mitomycin (FSM). Cancer 1986; 57: 29-33.
  26. Group GTS. Phase II study of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimes of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 1986; 4: 1794-8.
  27. Kinsella A, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites. a function of salvage pathway involvement and cellular responce to DNA damage. Br J Cancer 1997; 75: 935-45.
  28. Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer. Current status. Stem Cells 2000; 18: 166-75.
  29. Cheng Y, Nakayama K. Effects of 5-fluoro-2-deoxyuridine on DNA metabolism in Hela cells. Mol Pharmacol 1983; 23: 171-4.
  30. Mandel G. The incorporation of 5-fluorouracil into RNA and its molecular consequences. Progr Mol Subcellular Biol 1969: 82-135.
  31. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a Review. Oncologist 2002; 7: 288-323.
  32. Glimelius B, Hoffman K, Sjo¨ den PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
  33. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12.
  34. Ducreux M, Rougier P, Pignon J, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic cancer. Ann Oncol 2002; 13: 1185-91.
  35. Hidalgo M, Castellano DLP-A, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-92.
  36. Auerbach M, Wampler G, Lokich J, et al. Treatment of advanced pancreatic adenocarcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Ann Oncol 1997; 8: 439-44.
  37. Maisey N, Chau I, Cunningham D, et al. Multicenter rand-omised phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20: 3130-6.
  38. Reni M, Passoni M, Pancucci M, et al. Definitive results of a phase I/II trial of cisplatin, epirubicin, continuous-infusion fluorouracil and gemcitabine in stage IV pancreatic adeno-carcinoma. J Clin Oncol 2001; 19: 2679-86.
  39. Philip P, Zalupski MM, El-Rayes B, et al. Phase II study of gemcitabine, cisplatin and infusional 5 fluorouracil in patients with metastatic pancreatic cancer. Proc ASCO 2002; Abstract 590.
  40. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, atriple prodrug of 5-FU, in humans: the mechanism for tumour selective accumulation of 5-FU. Pharmacol Res 2001; 18: 1190- 202.
  41. Gieschke R, Reigner B, Blesch K, Steimer J. Population pharmacokinetic analysis of the major metabolites of cape-citabine. J Pharmacokinet Pharmacodyn 2002; 29: 25-47.
  42. Reigner B, Blesch K, Weidekamm E. clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85-104.
  43. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbonate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81.
  44. Liu G, Franssen M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
  45. Cartwright T, Cohn A, Varkey J, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20: 160-4.
  46. Hess V, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21: 66-8.
  47. Scheithauer W, Schull B, Ulrich-Pur H, et al. Bi-weekly hugh-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomised phase II trial. Ann Oncol 2003; 14: 97-104.
  48. Fujii S, Kitanio S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumour activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-14.
  49. Irenaka k Shirasaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353-9.
  50. Feliu J, Lopez Alarez M, Jaraiz M, et al. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancraetic carcinoma. Cancer 2000; 89: 1706-13.
  51. Okada S, Okusaka T, Ueno H, et al. A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (APC). ASCO, 2002; Abstract 682.
  52. Michael A, Hill M, et al. Preliminary results of phase I/II study to investigate the use of gemcitabine in combination with raltitrexed in locally advanced or metastatic adeno-carcinoma of the pancreas. Proc ASCO 2002; Abstract 675.
  53. Van Laethem J, Van Maele P, Polus M, et al. Raltirexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: a Belgian multicentre phase II study. ASCO, 2002; Abstract 547.
  54. Borner M, Kralidis E, Freiss H, Buchler M. Raltitrexed and gemcitabine: a phase II study in advanced pancreatic cancer. Proc ASCO 2002; Abstract 2206.
  55. Gunasekara N, Faulds D. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998; 55: 423-35.
  56. Smith D, Gallagher N, Garnett SA. Phase I/II trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer. Proc ASCO 2002; Abstract 574.
  57. Kindler H, Dugan W, Hochster HI, et al. Clinical outcomes in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc ASCO 2002: 499.
  58. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2,2-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
  59. Robertson JM, Shewach DS, Lawrence TS. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer 1996; 78: 674-9.
  60. Carmichael J, Fink U, Russell R, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-5.
  61. Casper E, Green M, Kelsen D, et al. Phase II trial of gemcitabine (2,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
  62. Rothenberg M, Moore M, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
  63. Berlin J, Catalano P, Thomas J, et al. (ECOG) ECOGT. A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncol Group (E2297). J Clin Oncol 2002; 20: 3270-5.
  64. Louvet C, Labianca R, Hammel P, et al. Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma: Interim results of the GERCOR/ GISCAD Intergroup Phase III. ASCO 2003. www.asco.org. : Abstract 1004.
  65. Rocha Lima CM, Rotche R, Jeffery M, et al. A randomised phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who had not yet received prior systemic therapy. ASCO 2003. Abstract 1005.
  66. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569-77.
  67. Scheithauer W, Schull B, Ulrich-Pur H, et al. Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Proc ASCO.2001. Abstract 500.
  68. Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101-3.
  69. Stathopoulos GP, Rigatos G, Kouroussis C, et al. Front line treatment with gemcitabine in combination with Irinotecan. preliminary results of a multicenter Phase II study. Proc ASCO 2000: 1260.
  70. Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60: 316-21.
  71. Heinemann V, Wilke H, Hg M, et al. Gemcitabine and cisp-latin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-403.
  72. Colucci G, Giuliani F, et al. Gemcitabine alone or with cisp-latin for the treatment of patients with locally advanced and/ or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncologia dell'Italia Merdionale. Cancer 2002; 94: 902-10.
  73. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaloplatin in advanced pancreatic adenocarcinoma. final results of a GERCOR multicenter Phase II study. J Clin Oncol 2002; 20: 1512-8.
  74. Alberts S, Townley P, Cha S, et al. Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group NCCTG) phase II study. Proc ASCO Abstract 501.
  75. Maiello E, Giuliani F, Valerio M. Oxaliplatin and gemcitabine combination therapy in advanced pancreatic cancer: preliminary results of a multicenter study of the Gruppo Oncologico Italia Meridionale (GOIM). Proc ASCO Abstract 2236.
  76. Touroutoglou N, Gravel D, Raber M, et al. Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumours. Ann Oncol 1998; 9: 1003-8.
  77. Tempero MA, Plunkett W, Ruiz van Haperen V, et al. Randomised phase II comparison of dose intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; in press.
  78. Grove K, Cheng Y. Uptake and metabolism of the new anti-cancer compound b-l-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 1996; 56: 4187.
  79. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD. The new dioxolane, (-)-2-deoxy-3-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000, 2002; 6: 1574-8.
  80. Lapointe R, Letourneau R, Steward WP. Phase II study of troxacitabine in chemotherapy naive patients with advanced cancer of the pancreas. Proc ASCO Abstract 565.
  81. Takahashi H, Nakashima A, Kanazawa J, et al. Metabolism and ribonucleotide reductase inhibition of (E)-2-deoxy-2-(fluoromethylene)cytidine. MDL 101,731 in human cervical carcinoma cells HeLa S3. Cancer Chemother Pharmacol 1998; 41: 268-74.
  82. Rodriguez G, Jones R, Orenberg E, Stoltz M, Brooks D. Phase I clinical trials of Tezacitabine [(E)-2-deoxy-2-(fluoromethyl-ene)cytidine] in patients with refractory solid tumours. Clin Cancer Res 2002; 8: 2828-34.
  83. Fichtinger-Schepman A, van der Veer J, den Hartog J, Lohman P, Reedijk J. Adducts of the anti-tumour drug cis-diamminedichloroplatinum(II) with DNA. Formation, identification and quantification. Biochemistry 1985; 24: 707-13.
  84. Crul M, van Waardenburg R, Bocxe S, et al. DNA repair mechanism involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003; 65: 275-82.
  85. Bergman A, Ruiz van Haperen V, Veerman G, Kuiper C, Peters G. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Can Res 1996; 17: 12-8.
  86. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumour marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-91.
  87. Conroy T, Paillot B, Francois E, et al. Final results of folfirinox: A triple combination of 5-FU/leucovorin (5-FU/LV), irinotecan (I) and oxaliplatin (O)] as first-line chemotherapy in advanced pancreatic adenocarcinoma (APA). ASCO www.asco/org/ac. Abstract 1045.
  88. Cantore M, Rabbi C, Cavazzini G. others. Irinotecan and oxaliplatin combination therapy in patients with advanced pre-treated pancreatic cancer. Proc ASCO Abstract 2197.
  89. Stephenson J, Scher R, Kosierowski R, et al. Phase II trial of topotecan as a 21 day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34: 1358-62.
  90. Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13: 347-54.
  91. Konstadoulakis M, Antonakis P, Tsibloulis B, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001; 48: 417-20.
  92. van den Neste E, de Valeriola D, Kerger J, et al. A phase I and pharmacokinetic study of docetaxel administrated in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumours. Clin Cancer Res 2000, 2002, 2002; 6: 64-71.
  93. Lutz M, Ducreux M, Wegener T, et al. Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma. a randomised phase II study of the EORTC-GI group. Proc ASCO Abstract 498.
  94. Schneider B, Ganjoo K, Seitz D, et al. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer - a Hoosier Oncology group study. Proc ASCO Abstract 546.
  95. Lenzi RL, Yalcin S, Evans D, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 2002; 20: 464-72.
  96. Ashamalla H, Zaki B, Mokhtar B, et al. Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55: 679-87.
  97. Safran H, Dipetrillo T, Iannitti D, et al. gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol 2002; 54: 137-41.
  98. Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach and gastro-oesophageal junction. Semin Radiat Oncol 1999; 9: 53-7.
  99. Bold R, Virudachalam S, McConkey D. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100: 11-7.
  100. Ling Y, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer 2002; 1: 841-9.
  101. Nawrocki S, Bruns C, Harbison M, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumour xenografts. Mol Cancer Ther 2002; 1: 1243-53.
  102. Ryan D, Eder JP, Winkelmann J, et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumours. Proc ASCO Abstract 379.
  103. Zugmaier G, Jager R, Grage B, Gottardis M, Havermann K, Knabbe C. Growth inhibiting effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996; 73: 1341-6.
  104. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W. Inhibition of tumour cell-induced angiogenesis by retinoids.1,25-dihydroxyvitamin D3 and their combination. Cancer Lett 1993; 75: 35-9.
  105. Evans T, Colston K, Lofts F, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002; 86: 680-5.
  106. Maitra A, Ashfaq R, Gunn C, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002; 118: 194- 201.
  107. Yip-Schneider M, Barnard D, Billings S, et al. Cyclo-oxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 139-46.
  108. Eling T, Thompson D, Foureman G, Curtis J, Hughes M. Prostaglandin H synthase and xenobiotic oxidation. Ann Rev Pharmacol Toxicol 1990; 30: 1-45.
  109. Plastarers J, Guengerich F, Nebet D, Marnett L. Xenobiotic metabolizing cytochrome P450 converts prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem 2000; 275: 11 784-90.
  110. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois R. Cyclo-oxygenase regulates angiogenesis induced by colorectal cancer celsl. Cell 1998; 93: 705-16.
  111. Tsujii M, Dubois R. Alterations in cellular adhesions and apoptosis in epithelial cell overexpressing prostaglandin endoperoxidase synthase 2. Cell 1995; 83: 493-501.
  112. Tsujii M, Kawano S, Dubois R. Cyclo-oxygenase-2 expression in known colorectal cancer cells and increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
  113. Eibl G, Ha R, Wente M, Hines O. The selective cyclo-oxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003; 26: 33-41.
  114. Subbaramaiah K, Dannenberg A. Cyclooxygenase-2. A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96-102.
  115. Patel V, Dunn M, Sorokin A. Regulation of MDR-1 (P glycoprotein) by cyclooxygenase-2. J Biol Chem 2002; 277: 38 915-20.
  116. Trifan O, Durham W, Salazar V, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumour efficacy and reduces diarrhoea side effect of CPY-11. Cancer Res 2002; 62: 5778-84.
  117. Lin E, Morris J, Ayers G. Effect of celecoxib on capecitabineinduced hand-foot syndrome and anti-tumour activity. Oncology (Huntingt)2002; 16: 31-7.
  118. Xiong HM, Wolff R, et al. Pharmacological study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc ASCO Abstract 448.
  119. Tong W, Ding X, Adrian T. Inhibition of human pancreatic cancer growth by lipooxygenase inhibitors in the athymic mouse xenograft model. Pancreas 2000; 21: 485.
  120. Ding X, Kuszynski C, El-Metwally T, Adrian T. Lipooxygenase inhibition induces apoptosis, morphological changes, and carbonic anhydrase in human pancreatic cancer cells. Biochem Biophys Res Commun 1999; 266: 392-9.
  121. Ferry D, Deakin M, Baddeley J, et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and oharnacodynamic endpoints. Ann Oncol 2000; 11: 1165-70.
  122. Tong W, Ding XZ, Hennig R, et al. Leukotiene B4 Receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002; 8: 3232-42.
  123. Hennig R, Ding XZ, Tong W, et al. 5-Lipoxygenase and LTB4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-8.
  124. Richards D, Waterhouse D, Wagener DJT, et al. Randomised, double blind, placebo controlled phase II study of the histone deacetylase inhibitor C1-994 plus gemcitabine (C1-994+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc ASCO Abstract 644.
  125. Magee CJ, Greenhalf W, Howes N, Ghaneh P, Neoptolemos J. Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg Oncol-Oxf 2002; 10: 1-23.
  126. van Cutsem E, Karasek P, Oettle H, et al. Phase III trial comparing gemcitabine + R115777 (Zarestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc ASCO Abstract 517.
  127. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with meta-static pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 1301-6.
  128. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14 459-64.
  129. Eskens F, Awada A, Cutler D, et al. Phase 1 and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH66336 given twice daily to patients with advanced solid tumours. J Clin Oncol 2001; 19: 1167-75.
  130. Adjei A, Erlichman C, Davis J, et al. A phase 1 trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000; 60: 1871-7.
  131. Matsuda K, Idezawa T, Juan You X, Kothari N, Fan H, Kore M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002; 62: 5611-7.
  132. Safran H, Steinhoff MM, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001; 24: 496-9.
  133. Kore M. Role of growth factors in pancreatic cancer. Surg Oncol Clin North Am 1998; 7: 25-41.
  134. Buchler P, Reber HA, Buchler M, et al. Therapy for pancreatic cancer with a recombinant humanised anti-HER-2 antibody (Herceptin). J Gastrointestinal Surg 2001; 5: 139-46.
  135. Safran H, Ramanathan RK, Schwartz J, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overex-press HER-2/neu. In: ASCO 2001 San Francisco: ASCO 2001.
  136. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc ASCO Abstract 518.
  137. Thomas CJ, Weiden P, Traverso, LW, et al. Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split course radiotherapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC). Am J Clin Oncol 1997; 20: 161-5.
  138. Nguyen T, Theobald S, Rourier P, et al. Simultanious high dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. Radiother Oncol 1997; 45: 129-32.
  139. Mehta VK, Poen JC, Ford JM, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001; 24: 155-9.
  140. Luderhoff E, Gonzalez D, Bakker P. Pilot study in locally advanced unresectable pancreas cancer using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. Radiother Oncol 1996; 40: 241-3.
  141. Prott F, Schonekaes K, Preusser P, et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas. Br J Cancer 1997; 75: 597-601.
  142. Wolff R, Evans DB, Gravel D, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Can Res 2001; 7: 2246-53.
  143. Ikeda M, Okada T, Tokuuye K, et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002; 86: 1551-4.
  144. Poggi M, Kroog G, Russo A, et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol 2002; 54: 670-6.
  145. Ashamalla H, Zaki B, Mokhtar B, et al. Hyperfrationationated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol, Biol, Phys 2003; 55: 679-87.
  146. Brunner T, Grabenbauer G, Klein P, et al. Phase I trial of strictly time scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol, Biol, Phys 2003; 55: 144-53.
  147. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002; 81: 138-43.
  148. Splinter TA, Obertop H, Kok TC, Jeekel J. Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study. J Cancer Res Clin Oncol 1989; 115: 200-2.
  149. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81: 102-7.
  150. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-68.
  151. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-85.
  152. Neoptolemos J, Stocken DD, JAD et al. Influence of the type of surgery and surgical complications in the ESPAC-1 adjuvant trial. Br J Surg 2002; 89: 35 (Abstract) .
  153. Neoptolemos JP, Moffitt DD, Dunn JA, et al. Survival and Quality of Life (QoL) of patients in ESPAC-1: a European, randomised study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. Gastroenterology 2001; 120: 118.
  154. Takada A, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicentre prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-95.
  155. Ishikawa O, Ohigashi H, Imaoka S, et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepato-Gastroenterology 1997; 44: 1541-6.
  156. Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994; 168: 361-4.
  157. Link KH, Formentini A, Gansauge F, Papachristov E, Beger HG. Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion 1997; 58: 529-32.
  158. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Adjuvant regional chemotherapy in resected advanced pancreas carcinoma. Chirurg 1996; 67: 362-5.
  159. Beger H, Gansauge F, Buchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer. significant reduction in occurrence of liver metastasis. World J Surg 1999; 23: 946-9.
  160. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
  161. Douglass HO Jr. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59: 2006-10.
  162. Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adeno-carcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999; 44: 1039-46.
  163. Regine W, John WJ, McGrath P, Strodel WE, Mohiuddin M. The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma. J Hepatobiliary Pancreatic Surg 2000; 7: 53-7.
  164. Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1483-7.
  165. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-82; discussion 782-4.
  166. Neoptolemos JP, Moffitt DD, Dunn JA, et al. Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: a European randomized trial to assess the rules of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. Br J Surg 2001; 88: 31.
  167. Gouma DJ, van Gulik TM, de Wit LT, Obertop H. Complications after resection of biliopancreatic cancer. Ann Oncol 1999; 10: 257-60.
  168. Berberat P, Freiss H, Kleef J, Uhl W, Buchler M. prevention and treatment of complications in pancreatic cancer surgery. Dig Surg 1999; 16: 327-36.
  169. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123-32.
  170. Hoffman JP, O'Dwyer P, Agarwal P, Salazar H, Ahmad N. Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective. Cancer 1996; 78: 592-7.
  171. Hoffman JP, Cooper HS, Young NA, Pendurthi TK. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreatic Surg 1998; 5: 251-4.
  172. White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999; 6: 38-45.
  173. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8: 758-65.
  174. Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II study. Cancer 1993; 72: 2124-33.
  175. Pendurthi TK, Hoffman J, Ross E, Johnson D, Eisenberg B. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998; 64: 686-92.
  176. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89: 314-27.
  177. Magnin V, Moutardier V, Giovannini M, et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1300-4.
  178. Kim H, Czischke K, Brennan M, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer. J Gastrointest Surg, 2002; 6: 763-9.
  179. Frey C, Twomey P, Keehn R, Elliott D, Higgins G. Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 1981; 47: 27-31.
  180. Heinemann V, Quietzsc F, Gieseler M et al. A, phase III trial comparing gemcitabine plus cisplatin vS. gemcitabine alone in advanced pancreatic canceR. Proc ASCO 2003: Abstract 1003.
  181. Ishikawa O, Ohhigashi H, Sasaki Y, Furukawa H, Imaoka S. Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas. Digestion 1999; 60: 135-8.
  182. Ozaki H, Kinoshita T, Kosuge T, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancreatol 2000; 27: 217-24.